FINWIRES · TerminalLIVE
FINWIRES

Nurix Therapeutics Gets $10 Million Milestone Payment as Sanofi Initiates Phase 1 Trial of STAT6 Degrader

By

Nurix Therapeutics (NRIX) said Tuesday it received a $10 million milestone payment from Sanofi (SNY) following the start of a phase 1 first-in-human clinical trial for SAR448272/NX-3911, an oral STAT6 degrader.

STAT6 plays a key role in interleukin-4 and interleukin-13 signaling pathways involved in type 2 inflammation and diseases such as atopic dermatitis and asthma, the company added.

With this payment, Nurix has received about $139 million under its 2019 collaboration deal with Sanofi, which is responsible for ongoing clinical development of SAR448272, it said.

Shares of Nurix Therapeutics rose nearly 5.4% and Sanofi was down 0.3% in the session.

Price: $24.46, Change: $+1.24, Percent Change: +5.34%

Related Articles

Wire

Ethos Q2 Adjusted Earnings, Revenue Rise; Q3 Guidance Set

Ethos (LIFE) reported Monday fiscal Q2 adjusted earnings of $0.53 per diluted share, up from $0.32 a year earlier.Four analysts polled by FactSet expected $0.33.Revenue for the quarter ended June 30 was $189.6 million, up from $88.8 million a year ago.Analysts expected $117.3 million.The company expects Q3 revenue of $160 million to $164 million. Analysts expect $120 million.For the full fiscal year 2026, Ethos now expects total revenue of $727 million to $731 million. Analysts expect $564.9 million.Ethos also announced that its board authorized a share repurchase program of up to $100 million of its outstanding Class A common stock.

$LIFE
Wire

Custom Truck One Source Swings to Q2 Profit, Revenue Rises; Shares Gain After Hours

Custom Truck One Source (CTOS) reported Q2 earnings late Monday of $0.05 per diluted share, compared with the loss of $0.13 a year earlier.Four analysts polled by FactSet expected earnings of $0.01.Revenue in the three months ended June 30 rose to $563.4 million from $511.5 million a year ago.Analysts surveyed projected $509.8 million.The company expects full-year revenue of $2.1 billion to $2.2 billion. Analysts project $2.05 billion.The company's shares jumped 10% in after-hours trading.

$CTOS
Wire

Alexandria Real Estate Equities Q2 Funds From Operations, Revenue Fall

Alexandria Real Estate Equities (ARE) reported Q2 funds from operations late Monday of $1.73 per diluted share, down from $2.33 a year earlier.Analysts polled by FactSet expected $1.64.Revenue in the three months ended June 30 fell to $662.8 million from $762 million a year earlier.Alexandria Real Estate projects Q4 adjusted funds from operations at the lower end of its previous guidance of $1.40 to $1.50 a share.The company expects 2026 adjusted funds from operations of $6.35 to $6.45 a share, compared with the previous forecast of $6.30 to $6.50.The company's shares rose 1.8% in after-hours trading.

$ARE